CVS Q3 2026 Earnings Analysis
CVS announced plans to separate into two independent companies by H1 2028 while raising full-year 2026 EPS to at least $8.20 on strong Medicare and pharmacy performance.
Key Metrics
Points clés
- CVS to split into CVS Health and CVS Pharmacy by H1 2028, each with tailored capital allocation strategies.
- Q3 adjusted EPS of $2.09 increased over 30% YoY; full-year 2026 EPS guidance raised to at least $8.20.
- Healthcare Benefits MBR improved 150 bps to 91.3%; 2027 Health Services guidance at least $7B AOI.
Écouter sur
Disponible en
Transcript
// Full episode scriptWelcome to Beta Finch, your AI-powered earnings breakdown, where we turn dense earnings calls into conversations you can actually enjoy. I'm Alex.
And I'm Jordan. And Alex, this is not a normal earnings call to kick off with.
Not even close. But before we get into it — quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Good, because today's news is a doozy.
It really is. CVS Health just announced on this Q3 2026 call that it's splitting into two separate, publicly traded companies — and they're targeting completion in the first half of 2028.
Let's break down who gets what. The first company keeps the "CVS Health" name and holds onto Aetna insurance, Caremark pharmacy services, specialty pharmacy, and the care-delivery pieces — Oak Street Health and Signify Health.
So basically the insurance, PBM, and value-based-care engine.
Exactly. Then the second company, which will be called "CVS Pharmacy," gets the retail stores, mail-order pharmacy, MinuteClinic, and this AI platform called Health 100.
Prem Shah, who currently runs retail, is going to be CEO of that new CVS Pharmacy company. David Joyner stays on as Chairman and CEO of the CVS Health side.
And importantly — management says this is expected to be tax-free for shareholders under U.S. federal rules, and existing CVS shareholders will end up owning shares in both new companies once it closes.
CEO David Joyner was very clear this isn't a distress move. He kept hammering the point that they're doing this "from a position of strength."
And honestly, the numbers back that up. Let's talk financials, because the quarter itself was strong, split announcement aside. Revenue came in north of $108 billion for the quarter.
Adjusted operating income was about $4.2 billion, and adjusted EPS was $2.09 — that's up more than 30% year-over-year.
Big jump. And because of that momentum, they raised full-year 2026 adjusted EPS guidance to at least $8.20, up from the prior range of $7.90 to $8.10.
They also bumped full-year cash flow from operations guidance to at least $15.5 billion. CFO Brian Newman pointed out that's over $5.5 billion higher than their original expectation for the year. That's a massive raise.
Segment by segment, it's a good story too. Healthcare Benefits — that's the Aetna insurance piece — posted adjusted operating income of $900 million, up almost $600 million from last year, with the medical benefit ratio improving about 150 basis points to 91.3%.
That's the Medicare Advantage turnaround everyone's been watching. Executive Steven Nelson said Aetna is actually moving into profitable territory in Medicare Advantage in 2026, after a rough couple of years.
Health Services — that's Caremark and specialty pharmacy — delivered $2.1 billion in adjusted operating income, up nearly 3%. And Pharmacy and Consumer Wellness, the retail side, had a really strong quarter: over $1.6 billion in operating income, up more than 10%, driven by almost 4% growth in same-store prescription volumes.
And get this — GLP-1 prescription volume at retail grew 23% in the quarter. That's a real tailwind.
Now let's talk balance sheet, because this matters a lot for the breakup story. They hit their target leverage ratio ahead of schedule, and because of that, they're resuming share buybacks in the fourth quarter.
Which tells you they're not strapped for cash heading into this separation — they actually have room to return capital to shareholders while also funding two standalone companies.
Let's jump into the Q&A, because analysts pushed hard on the "why now" and "what about the dis-synergies" questions. JPMorgan's Lisa Gill basically asked, why split now instead of staying together like you have for 20 years since the Caremark deal?
Joyner's answer was pretty candid — he said two years ago they were in crisis mode, Medicare was struggling, retail was guiding to negative 5% growth. They simply weren't in a position to make a decision like this. Now, with eight straight quarters of beat-and-raise and a repaired balance sheet, they have the luxury of choosing their structure rather than being forced into one.
There was also a great question from Michael Cherny at Leerink about losing the "synergy magic" between CVS retail and Caremark — remember things like Maintenance Choice, where the PBM and the stores worked together.
Joyner's answer: they're not operationally integrating those two today anyway — retail has always negotiated with Caremark at arm's length, like outside vendors. So they'll preserve that value through commercial agreements between the two new companies instead of needing them under one roof.
And the connective tissue going forward, they say, is this Health 100 platform — basically an AI consumer engagement tool meant to tie together the pharmacy side's foot traffic with the insurance side's data and underwriting.
There was also pointed questioning on 340B — that's the drug discount program for safety-net providers — and on PBM client attrition. Management set a 2027 floor for the Health Services segment of at least $7 billion in adjusted operating income, calling 2027 the "trough" year before returning to growth, driven partly by 340B headwinds and some Medicare PDP-related membership losses.
They also gave an early look at 2027 overall: adjusted EPS of at least $8.65, which is about 13% growth off the 2026 base — and they said they now expect to land at the high end of the mid-teens EPS growth target they laid out at Investor Day through 2028.
On the cost side, Wells Fargo's Steven Baxter asked about potential dis-synergies from splitting — stranded costs, duplicate public-company overhead, that kind of thing. Brian Newman said those costs are "manageable" and already baked into guidance, and he expects the strategic value created to outweigh them over time.
So what does this all mean for investors going forward? You've essentially got a company telling you: "We're healthy enough now to become two healthier, more focused companies." The insurance-and-PBM side gets to concentrate on affordability and value-based care in a massive $2 trillion-plus market, while the pharmacy side becomes a focused, cash-generative retail health leader in a $500 billion-plus market.
The real work now is execution over the next 15 to 18 months — separating balance sheets, standing up two investment-grade capital structures, and making sure those commercial agreements between the two companies actually preserve the value that integration used to provide.
Before we wrap — one more required note. Everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
Big news day for CVS, and a long runway ahead before this split actually happens in 2028. We'll be watching the February call for more detail on 2027 guidance and how this separation process is unfolding.
Until next time, this has been Beta Finch.
Thanks for listening — we'll catch you on the next one.